Intranasal delivery of a ROS-activatable myeloperoxidase inhibitor alleviates Alzheimer’s-like symptoms and pathology

Chronic neuroinflammation and oxidative stress are important contributors to Alzheimer's disease (AD). Myeloperoxidase (MPO), a key driver of oxidative inflammation released mainly by activated microglia in the neurodegenerative brain, is a potential therapeutic target to inhibit the neuroinflammatory cascade and oxidative damage in AD, but the underlying mechanisms remain unexplored, and achieving targeted brain delivery of an MPO inhibitor and minimizing systemic effects remain significant challenges. We addressed these limitations by first establishing that genetic deletion of MPO in the 5XFAD mouse model improved memory performance and reduced amyloid deposition, validating MPO as a therapeutic target. We then developed a liposome-encapsulated reactive oxygen species (ROS)-activatable MPO inhibitor (LERAMI). LERAMI uniquely combines targeted delivery with on-demand drug release, utilizing a ROS-sensitive linker to selectively release MPO inhibitors in ROS-rich regions within the AD microenvironment, minimizing off-target effects and systemic toxicity. In the 5XFAD mouse model. By reducing MPO expression and activity, LERAMI significantly improved cognitive performance, accompanied by decreased microglial activation, attenuated oxidative DNA damage, improved synaptic and neuronal density, and reduced amyloid burden. RNA sequencing revealed a robust hippocampal transcriptomic reprogramming, with upregulation of pathways critical for synaptic plasticity, calcium signaling, axon guidance, and neuroprotection, along with downregulation of inflammatory and immune response pathways. These findings demonstrate that targeted ROS-activatable MPO inhibition with LERAMI represents a promising therapeutic strategy for AD and potentially other neuroinflammatory diseases, offering a unique approach to mitigate neuroinflammation, preserve synaptic integrity, and restore cognitive function.

Authors

Institutions

Publication Details

Journal
Proceedings of the National Academy of Sciences
Published
2026-11-17
DOI
https://doi.org/10.1073/pnas.2603280123
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Intranasal delivery of a ROS-activatable myeloperoxidase inhibitor alleviates Alzheimer’s-like symptoms and pathology

Peilin Cong, Dalong Ni, John W. Chen, Matthias W. G. Zeller et al.
1 links
Proceedings of the National Academy of Sciences
Alzheimer's disease research and treatments
article

Intranasal delivery of a ROS-activatable myeloperoxidase inhibitor alleviates Alzheimer’s-like symptoms and pathology

Peilin Cong, Dalong Ni, John W. Chen, Matthias W. G. Zeller, Yifan Lv, Negin Jalali Motlagh, Yu Luo, Lize Xiong, Jenny Linnoila, He Wang, Jing Wang, Qian Chen, Han Wang, Ke Gao, Cuihua Wang, Zhiming Xu, Enduo Feng, Boyu Zhang
article en

Abstract

Chronic neuroinflammation and oxidative stress are important contributors to Alzheimer's disease (AD). Myeloperoxidase (MPO), a key driver of oxidative inflammation released mainly by activated microglia in the neurodegenerative brain, is a potential therapeutic target to inhibit the neuroinflammatory cascade and oxidative damage in AD, but the underlying mechanisms remain unexplored, and achieving targeted brain delivery of an MPO inhibitor and minimizing systemic effects remain significant challenges. We addressed these limitations by first establishing that genetic deletion of MPO in the 5XFAD mouse model improved memory performance and reduced amyloid deposition, validating MPO as a therapeutic target. We then developed a liposome-encapsulated reactive oxygen species (ROS)-activatable MPO inhibitor (LERAMI). LERAMI uniquely combines targeted delivery with on-demand drug release, utilizing a ROS-sensitive linker to selectively release MPO inhibitors in ROS-rich regions within the AD microenvironment, minimizing off-target effects and systemic toxicity. In the 5XFAD mouse model. By reducing MPO expression and activity, LERAMI significantly improved cognitive performance, accompanied by decreased microglial activation, attenuated oxidative DNA damage, improved synaptic and neuronal density, and reduced amyloid burden. RNA sequencing revealed a robust hippocampal transcriptomic reprogramming, with upregulation of pathways critical for synaptic plasticity, calcium signaling, axon guidance, and neuroprotection, along with downregulation of inflammatory and immune response pathways. These findings demonstrate that targeted ROS-activatable MPO inhibition with LERAMI represents a promising therapeutic strategy for AD and potentially other neuroinflammatory diseases, offering a unique approach to mitigate neuroinflammation, preserve synaptic integrity, and restore cognitive function.

Proceedings of the National Academy of SciencesVol. 123(47)
Tongji University (CN), Harvard University (US), Massachusetts General Hospital (US), Center for Systems Biology (US)
Natural Science Foundation of Shanghai, National Natural Science Foundation of China, National Institute on Aging, National Institute of Neurological Disorders and Stroke
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon